GE Healthcare Obtains License for c-Met Peptides from Dyax | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dyax is granting GE Healthcare rights to develop and commercialize c-Met imaging peptides for potential use in patient selection under a deal announced today.

Under the terms of the deal, GE will pay biopharmaceutical firm Dyax upfront, milestone, and royalty payments. Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.